Immunotherapeutic approaches in hepatocellular carcinoma: building blocks of hope in near future

Basit Öğe Kaydı
dc.authoridAli Zarrabi / 0000-0003-0391-1769en_US
dc.authorscopusidAli Zarrabi / 23483174100en_US
dc.authorwosidAli Zarrabi / U-2602-2019en_US
dc.contributor.authorMinaei, Neda
dc.contributor.authorRamezankhani, Roya
dc.contributor.authorTamimi, Atena
dc.contributor.authorPiryaei, Abbas
dc.contributor.authorZarrabi, Ali
dc.contributor.authorAref, Amir Reza
dc.contributor.authorMostafavi, Ebrahim
dc.contributor.authorVosough, Massoud
dc.date.accessioned2023-01-07T12:42:41Z
dc.date.available2023-01-07T12:42:41Z
dc.date.issued2023en_US
dc.departmentİstinye Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Biyomedikal Mühendisliği Bölümüen_US
dc.description.abstractHepatocellular carcinoma (HCC) is the most common type of primary hepatic cancer and is among the major causes of mortality due to cancer. Due to the lack of efficient conventional therapeutic options for this cancer, particularly in advanced cases, novel treatments including immunotherapy have been considered. However, despite the encouraging clinical outcomes after implementing these innovative approaches, such as oncolytic viruses (OVs), adoptive cell therapies (ACT), immune checkpoint blockades (ICBs), and cancer vaccines, several factors have restricted their therapeutic effect. The main concern is the existence of an immunosuppressive tumor microenvironment (TME). Combination of different ICBs or ICBs plus tyrosine kinase inhibitors have shown promising results in overcoming these limiting factors to some extent. Combination of programmed cell death ligand-1 (PD-L1) antibody Atezolizumab and vascular endothelial growth factor (VEGF) antibody Bevacizumab has become the standard of care in the first-line therapy for untestable HCC, approved by regulatory agencies. This paper highlighted a wide overview of the direct and indirect immunotherapeutic strategies proposed for the treatment of HCC patients and the common challenges that have hindered their further clinical applications. © 2022 The Authorsen_US
dc.identifier.citationMinaei, N., Ramezankhani, R., Tamimi, A., Piryaei, A., Zarrabi, A., Aref, A. R., ... & Vosough, M. (2022). Immunotherapeutic Approaches in Hepatocellular Carcinoma: Building Blocks of Hope in Near Future. European Journal of Cell Biology, 151284.en_US
dc.identifier.doi10.1016/j.ejcb.2022.151284en_US
dc.identifier.issn0171-9335en_US
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85145034400en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttp://dx.doi.org/10.1016/j.ejcb.2022.151284
dc.identifier.urihttps://hdl.handle.net/20.500.12713/3813
dc.identifier.volume102en_US
dc.identifier.wosWOS:000916700000001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorZarrabi, Ali
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofEuropean Journal of Cell Biologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdoptive Cell Therapyen_US
dc.subjectCancer Immunotherapyen_US
dc.subjectCancer Vaccineen_US
dc.subjectHepatocellular Carcinomaen_US
dc.subjectImmune Checkpoint Blockadesen_US
dc.subjectOncolytic Virusesen_US
dc.titleImmunotherapeutic approaches in hepatocellular carcinoma: building blocks of hope in near futureen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
1-s2.0-S0171933522000875-main.pdf
Boyut:
4.6 MB
Biçim:
Adobe Portable Document Format
Açıklama:
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Biyomedikal Mühendisliği Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu